Russom Mulugeta, Tesfaselassie Hager, Goitom Rozina, Ghirmai Tadese, Weldedhawariat Freweini, Berhe Abiel, Tesfai Dawit, Debesai Merhawi, Berhane Tesfit, Woldu Henok G
Eritrean Pharmacovigilance Centre, National Medicines and Food Administration, Asmara, Eritrea.
School of Public Health, Asmara College of Health Sciences, Asmara, Eritrea.
Tuberc Res Treat. 2019 May 21;2019:9429213. doi: 10.1155/2019/9429213. eCollection 2019.
Though the incidence of gout in general population is less than 5% (globally), a study conducted in Eritrea among patients with multidrug resistant tuberculosis (MDR-TB) revealed a higher incidence (25%). Other similar studies conducted elsewhere, however, did not report gout as an adverse effect. It is unknown why a higher incidence of gout is being reported in Eritrea compared to similar studies from other countries. The objective of this study is therefore to explore risk factors for the increased risk of incident gout among MDR-TB patients in Eritrea. A case-control study was conducted in Merhano MDR-TB National Referral Hospital in Eritrea. All MDR-TB patients diagnosed with gout between June 2011 and June 2018 were considered as cases. Controls matched by age, sex, and cumulative drug exposure time were selected from the same study population (1:1 ratio). A total of 84 MDR-TB patients, 42 cases and 42 controls, were included in this study. No patient from the control group has comorbidities, while six patients from the case group have diabetes (2 = 6.46, df=1, p=0.026). Patients having tachycardia (OR=3.26, 95% CI=1.28, 8.27), alopecia (OR=3.11, 95% CI=1.00, 9.67), and gastrointestinal upset (OR=3.17, 95% CI=1.26, 7.96) as adverse effects and being on prolonged use of propranolol (OR=3.26, 95% CI=1.28, 8.27) were found to be more likely to develop incident gout compared to their controls. In conclusion, MDR-TB patients with diabetes mellitus, tachycardia, alopecia, and gastrointestinal upset and on prolonged use of propranolol tablet had increased risk of incident gout.
尽管痛风在普通人群中的发病率低于5%（全球范围），但在厄立特里亚对耐多药结核病（MDR-TB）患者进行的一项研究显示发病率更高（25%）。然而，在其他地方进行的其他类似研究并未将痛风报告为一种不良反应。与其他国家的类似研究相比，厄立特里亚报告的痛风发病率更高的原因尚不清楚。因此，本研究的目的是探讨厄立特里亚耐多药结核病患者新发痛风风险增加的危险因素。在厄立特里亚的梅尔哈诺耐多药结核病国家转诊医院进行了一项病例对照研究。2011年6月至2018年6月期间所有被诊断患有痛风的耐多药结核病患者被视为病例。从同一研究人群中按年龄、性别和累积药物暴露时间匹配选择对照（1:1比例）。本研究共纳入84例耐多药结核病患者，42例病例和42例对照。对照组中没有患者患有合并症，而病例组中有6例患者患有糖尿病（χ² = 6.46，自由度 = 1，p = 0.026）。与对照组相比，出现心动过速（比值比[OR]=3.26，95%置信区间[CI]=1.28，8.27）、脱发（OR=3.11，95% CI=1.00，9.67）和胃肠道不适（OR=3.17，95% CI=1.26，7.96）等不良反应以及长期使用普萘洛尔（OR=3.26，95% CI=1.28，8.27）的患者更有可能发生新发痛风。总之，患有糖尿病、心动过速、脱发和胃肠道不适且长期使用普萘洛尔片的耐多药结核病患者新发痛风的风险增加。
